What Is PDGF Growth Factor and What Does It Do?

Platelet-derived growth factor, or PDGF, is a signaling protein that tells certain cells in the body to grow, move, and divide. It was originally discovered inside the small storage compartments of blood platelets, where it waits to be released at the site of an injury, but researchers have since found that many other cell types produce it too. PDGF turns out to be one of the body’s central orchestrators of tissue repair, blood vessel formation, and organ development, and its misbehavior is implicated in diseases ranging from atherosclerosis to cancer.

Where PDGF Comes From

The name gives away PDGF’s origin story. Scientists first identified it while studying platelets, the tiny cell fragments in blood that clump together to stop bleeding. When platelets activate at a wound site, they release PDGF from internal storage compartments called alpha granules, essentially dumping a chemical signal into the surrounding tissue that says “start repairing.”¹ But platelets are far from the only source. Vascular smooth muscle cells, certain kidney cells, and various immune cells also produce PDGF on their own.² In the brain, astrocytes and neurons secrete a particular form of PDGF that governs the behavior of the cells responsible for insulating nerve fibers.³ So while the platelet connection gave PDGF its name, the protein is really a widespread tissue-level communicator.

The PDGF Family

PDGF is not one molecule but a family of five. The body encodes four different PDGF protein chains, labeled A, B, C, and D, and these chains pair up into five combinations: PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD. Each pair is held together by chemical bonds between sulfur atoms in the chains.⁴ These five versions don’t all do the same thing. They plug into two different receptor proteins on cell surfaces, called PDGF receptor alpha and PDGF receptor beta. The alpha receptor is more of a generalist and responds to several PDGF forms, while the beta receptor is pickier and responds most strongly to PDGF-BB and PDGF-DD. The combination of which PDGF version is present and which receptor a given cell carries determines exactly what signal the cell receives.

Structural studies have shown that when PDGF binds its receptor, two receptor molecules are clamped together at the point where the two PDGF chains meet, forming a bridge that activates the receptor’s internal signaling machinery.⁵ This receptor bridging is what triggers the downstream cascade of events inside the cell. Blocking that bridge, either with drugs or antibodies against the receptor, shuts down the PDGF signal and can reduce effects like cell migration and tissue remodeling.⁶

What Happens Inside the Cell

Once a PDGF molecule docks onto its receptor, the receptor fires up several internal signaling pathways. Among the most important are the PI3K/Akt pathway, which promotes cell survival, and the MAP kinase pathway (including ERK, JNK, and p38), which drives cell growth and movement. In neurons, PDGF-BB strongly activates all of these pathways, while PDGF-AA triggers them more weakly, especially the survival-promoting Akt pathway.⁷ The same basic signaling machinery operates in blood vessel walls, where PDGF-BB causes smooth muscle cells and small blood vessels to contract through a combination of calcium signaling and prostaglandin release.⁸

The practical upshot is that PDGF tells cells three things: stay alive, multiply, and move toward wherever the signal is strongest. These three instructions make PDGF essential for building and repairing tissue, but they also explain why PDGF overactivity causes problems. A cell that won’t stop dividing or migrating is the seed of fibrosis or cancer, as we’ll see below.

PDGF and Wound Healing

The role PDGF plays in wound healing is the one it was essentially designed for, at least from an evolutionary standpoint. When you cut yourself, platelets arrive first, stick together, and release PDGF into the wound. That signal recruits two cell types critical for repair: immune cells called monocytes and macrophages, which clean up debris and fight infection, and fibroblasts, the cells that lay down the structural framework for new tissue. Animal experiments showed that applying even tiny amounts of PDGF-BB to a wound sped up both the arrival of inflammatory cells and the formation of new connective tissue, with visibly more granulation tissue by about four days and significantly more mature collagen by two weeks compared to untreated wounds.⁹¹⁰

PDGF doesn’t work alone in wound repair. It acts alongside other growth factors, particularly VEGF (which builds new blood vessels to supply the healing tissue) and TGF-beta (which regulates scarring and immune responses). Research on diabetic wounds has found that these three signals work in concert: disrupting one can impair the others.¹¹ This crosstalk also applies outside wounds. In blood vessels under low-flow conditions, both PDGF-BB and TGF-beta production increase, driving the kind of vessel wall remodeling that can be adaptive in some situations but harmful in others.¹²

Building an Embryo

PDGF isn’t just a repair signal for adults. It plays an essential role during embryonic development, particularly in building blood vessels. As new vessels form in an embryo, they need to recruit smooth muscle cells and pericytes (the cells that wrap around small capillaries, providing structural support). Mouse embryos lacking either the gene for PDGF-B or for its beta receptor develop blood vessels that are missing these supporting cells at specific locations, leading to fragile, poorly formed vasculature.¹³ Without PDGF-B signaling, the body can start forming blood vessels but can’t properly stabilize them, which is why these knockout embryos typically don’t survive.

In the developing brain, a different family member takes center stage. PDGF-A acts as the primary growth signal for oligodendrocyte progenitor cells, the precursors to the cells that produce myelin, the insulating sheath around nerve fibers. The supply of PDGF-A controls how many of these progenitor cells the brain generates, both during development and in adulthood. Mice engineered to overproduce PDGF-A in their brains ended up with far more oligodendrocyte progenitor cells than normal, especially in the brain’s white matter tracts.¹⁴ This finding has implications for conditions involving myelin damage, like multiple sclerosis, where boosting PDGF-A might help replenish the cells needed for remyelination.

Medical Uses of PDGF

The clearest clinical application of PDGF is in chronic wounds that refuse to heal. Becaplermin, a gel containing lab-made PDGF-BB, was approved for treating diabetic foot ulcers. In a large clinical trial, patients who received becaplermin gel had a 43% higher rate of complete wound closure compared to those getting a placebo gel (about half the treated patients healed versus about a third of controls), and the time to closure dropped by roughly a third.¹⁵ For people living with diabetic neuropathy who develop chronic sores, this is a meaningful clinical improvement.

Dentistry and orthopedics have also adopted PDGF-based treatments. Recombinant PDGF-BB applied to bone defects around teeth stimulates bone turnover and promotes regeneration of the periodontal tissue that anchors teeth in the jaw.¹⁶ Reviews of the evidence support using PDGF-enhanced scaffolds for both periodontal repair and bone regeneration around dental implants.¹⁷ The idea behind platelet-rich plasma (PRP) injections, commonly marketed for sports injuries and joint pain, partly rests on the same principle: concentrating platelets means concentrating their PDGF payload, which could theoretically accelerate tissue repair in tendons, muscles, and ligaments. The clinical evidence for PRP remains more mixed than the marketing suggests, but the biological rationale traces directly back to PDGF’s tissue-repair properties.

When PDGF Drives Fibrosis

If wound healing is PDGF doing its job properly, fibrosis is what happens when it doesn’t know when to stop. Fibrosis, the excess accumulation of scar-like tissue, occurs when the cells responsible for laying down structural proteins keep getting activated long after the original injury has passed. PDGF signaling is one of the central pathways driving this process. The connective-tissue cells called fibroblasts and their activated cousins, myofibroblasts, carry both PDGF receptors, and when those receptors keep firing, the cells proliferate, migrate into the tissue, and crank out extracellular matrix at an abnormal rate.¹⁸

This matters across several organs. In the liver, chronic damage from hepatitis, alcohol, or fatty liver disease activates stellate cells, which are the liver’s version of fibroblasts. Both PDGF-B and PDGF-D are potent growth signals for these cells, fueling the deposition of scar tissue that can eventually progress to cirrhosis.¹⁹ Similar fibrotic processes driven by PDGF have been described in the lungs, kidneys, and skin. The common thread is that the same “grow, move, build” signal that repairs a wound after a one-time injury becomes destructive when it runs chronically.

PDGF in Atherosclerosis and Heart Disease

The connection between PDGF and cardiovascular disease actually predates most other PDGF research. The growth factor was originally discovered in the 1970s while scientists were investigating what drives the formation of atherosclerotic plaques, the fatty, fibrous buildups that narrow arteries and cause heart attacks and strokes. The smooth muscle cells that line blood vessels are normally quiescent, sitting in a contractile state that lets the vessel function properly. PDGF-BB pushes these cells to switch from that quiet mode into an active, proliferative state, causing them to multiply, migrate into the vessel wall, and contribute to plaque growth.²⁰

Making things worse, PDGF-activated smooth muscle cells also produce tissue factor, a protein that promotes blood clotting. This links PDGF not just to the slow buildup of plaque over decades but also to the acute event of plaque rupture and clot formation that causes a heart attack.²¹ The same process, abnormal smooth muscle cell behavior driven by PDGF, also contributes to the re-narrowing that sometimes occurs after vein grafts or surgical procedures on blood vessels.²²

PDGF and Cancer

The same properties that make PDGF useful in wound healing, promoting cell survival, growth, and migration, also make it potentially dangerous in the context of cancer. In certain tumors, genetic accidents cause PDGF or its receptors to become permanently switched on. One well-studied example is dermatofibrosarcoma protuberans (DFSP), a rare skin tumor driven by a chromosomal rearrangement that fuses a PDGF gene to a partner that forces continuous PDGF production. The tumor effectively feeds itself by bathing its own cells in growth signals.²³

The DFSP story has a relatively happy ending, though. Because the tumor is driven almost entirely by this one signaling loop, blocking it with a drug like imatinib, which inhibits the PDGF receptor, can shrink or control the disease.²⁴ A similar principle applies to certain gastrointestinal stromal tumors (GISTs), which are sometimes driven by mutations in the PDGF receptor alpha gene. Imatinib and related drugs like nilotinib work against some of these mutations, though effectiveness varies depending on exactly which mutation the tumor carries.²⁵ The lesson from both tumor types is that PDGF-driven cancers can be particularly vulnerable to targeted therapy, precisely because they depend so heavily on one pathway.

The Evolutionary Roots of PDGF

PDGF is not a recent evolutionary invention. It belongs to a larger superfamily of proteins called cystine knot growth factors, which share a distinctive structural feature: a knot-like arrangement of chemical bonds that gives the protein exceptional stability. PDGF and VEGF (the vascular growth factor best known for building new blood vessels) are close evolutionary cousins within this superfamily. Researchers tracing PDGF/VEGF genes across the animal kingdom have found versions of them in nearly every animal phylum, suggesting the ancestral gene predates the split between vertebrates and invertebrates by hundreds of millions of years.²⁶ The whole-genome duplications that occurred early in vertebrate evolution then expanded this family, producing the four distinct PDGF genes we carry today. This deep conservation underscores how fundamental PDGF’s roles in building and maintaining blood vessels and connective tissue are to animal life.

PDGF in Neuroprotection

Beyond its well-known roles in blood vessels and connective tissue, PDGF has a quieter job in the nervous system that researchers have found increasingly interesting. Neurons themselves carry the PDGF beta receptor, and PDGF-BB appears to protect them against oxidative stress, the kind of cellular damage caused by reactive oxygen molecules that accumulates during aging and in neurodegenerative conditions. In experiments on cultured neurons, blocking the PDGF beta receptor made cells more vulnerable to oxidative damage, while adding PDGF-BB rescued them, primarily by activating the Akt survival pathway.⁷ This neuroprotective angle is still largely preclinical, but it suggests that the same growth factor known for patching up skin wounds and building blood vessels might also help keep aging neurons alive. Whether that can be harnessed therapeutically remains an open question, but it illustrates the breadth of PDGF’s influence across tissues that seem, at first glance, to have little in common.